Kestrel Buttress Plate System
K181063 · Innovasis, Inc. · KWQ · Jul 13, 2018 · Orthopedic
Device Facts
| Record ID | K181063 |
| Device Name | Kestrel Buttress Plate System |
| Applicant | Innovasis, Inc. |
| Product Code | KWQ · Orthopedic |
| Decision Date | Jul 13, 2018 |
| Decision | SESE |
| Submission Type | Traditional |
| Regulation | 21 CFR 888.3060 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Intended Use
The Kestrel™ Buttress Plate System is indicated for use to stabilize the allograft at one level (L1-S1) as an aid to spinal fusion and to provide temporary stabilization and augment of a solid spinal fusion. It may be used alone or with other anterior, or anterolateral spinal systems made of compatible materials. This device is not intended for load bearing applications.
Device Story
Kestrel™ Buttress Plate System is a temporary spinal implant consisting of plates and bone screws; designed to prevent allograft or autograft extrusion or interbody fusion device (IBFD) expulsion. Implanted on the anterior portion of the lumbar vertebral body (L1-S1). Used by orthopedic surgeons in hospitals or surgical centers. Provides temporary stabilization and augments solid spinal fusion; can be used alone or with other compatible anterior/anterolateral spinal systems. Not intended for load-bearing. Benefits include preventing graft migration and supporting fusion development.
Clinical Evidence
Bench testing only. Performance testing included static and dynamic cantilever bend, torque to failure, and axial pullout testing.
Technological Characteristics
Constructed from Titanium 6 Al 4V ELI per ASTM F136. System consists of plates and bone screws for anterior lumbar fixation. Mechanical testing performed to verify strength.
Indications for Use
Indicated for patients requiring spinal fusion at one level (L1-S1) to stabilize allograft or autograft and provide temporary stabilization. Not intended for load-bearing applications.
Regulatory Classification
Identification
A spinal intervertebral body fixation orthosis is a device intended to be implanted made of titanium. It consists of various vertebral plates that are punched into each of a series of vertebral bodies. An eye-type screw is inserted in a hole in the center of each of the plates. A braided cable is threaded through each eye-type screw. The cable is tightened with a tension device and it is fastened or crimped at each eye-type screw. The device is used to apply force to a series of vertebrae to correct “sway back,” scoliosis (lateral curvature of the spine), or other conditions.
Predicate Devices
- Precision Spine RCS Anterior Buttress Plate System (K092659)
Related Devices
- K173091 — Boundary Anterior Lumbar Buttress Plate · Nvision Biomedical Technologies, LLC · Dec 6, 2017
- K092659 — SPINAL USA RCS ANTERIOR LUMBAR BUTRESS PLATE SYSTEM, MODEL 22-1001-25 · Spinal USA · Nov 17, 2009
- K133911 — GENESYS SPINE ANTERIOR BUTTRESS PLATE SYSTEM · Genesys Spine · Sep 3, 2014
- K232256 — Alcantara Thoracolumbar Plate System · Camber Spine Technologies, LLC · Apr 16, 2024
- K180755 — Vail ALIF Buttress Plate System · Evolution Spine, LLC · Jul 6, 2018
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" followed by the words "U.S. FOOD & DRUG ADMINISTRATION".
Innovasis, Inc. Mr. Marshall McCarty Director QA/RA 614 East 3900 South Salt Lake City, Utah 84107
Re: K181063
Trade/Device Name: Kestrel™ Buttress Plate System Regulation Number: 21 CFR 888.3060 Regulation Name: Spinal Intervertebral Body Fixation Orthosis Regulatory Class: Class II Product Code: KWQ Dated: June 21, 2018 Received: June 22, 2018
Dear Mr. McCarty:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov
July 13, 2018
{1}------------------------------------------------
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
# Brent Showalter -S
for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
# Indications for Use
510(k) Number (if known) K181063
Device Name Kestrel™ Buttress Plate System
#### Indications for Use (Describe)
The Kestrel™ Buttress Plate System is indicated for use to stabilize the allograft at one level (L1-S1) as an aid to spinal fusion and to provide temporary stabilization and augment of a solid spinal fusion. It may be used alone or with other anterior, or anterolateral spinal systems made of compatible materials. This device is not intended for load bearing applications.
Type of Use (Select one or both, as applicable)
| <span></span> | Prescription Use (Part 21 CFR 801 Subpart D) |
|---------------|----------------------------------------------|
| <span></span> | Over-The-Counter Use (21 CFR 801 Subpart C) |
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
# 510(k) Summary
### Kestrel™ Buttress Plate System
Company: Innovasis, Inc. 614 E. 3900 South Salt Lake City, UT 84107
- Marshall C. McCarty Contact: Phone: (801) 261-2236 mmccarty@innovasis.com
- Kestrel™ Buttress Plate System Trade Name:
- Common Name: Buttress Plate System
- Classification: Regulation No.: 21CFR 888.3060 Class II Product Code: KWQ Review Panel: Orthopedic
- Predicate Device: K092659 - Precision Spine RCS Anterior Buttress Plate System This predicate has not been subject to a design-related recall.
- Device Description: The Innovasis Kestrel™ Buttress Plate System is a temporary implant used to prevent allograft or autograft extrusion or IBFD expulsion. The Kestrel Buttress Plate System consists of plates and bone screws. The Kestrel System is also intended to provide stabilization and augment development of a solid spinal fusion. The Kestrel Buttress Plate System fixates to the anterior portion of the lumbar vertebral body. The construct may be employed alone or with other anterior, or anterolateral spinal systems made of compatible materials.
- Performance Data: (Non-clinical)—Performance testing includes static and dynamic cantilever bend, torque to failure and axial pullout.
- Materials: Titanium 6 Al 4V ELI per ASTM F136.
- The Innovasis Kestrel™ Buttress Plate System is intended for use Intended Use: in the lumbar spine (L1-S1). Users of these products are limited to physicians trained in
orthopedic surgery. Clinical locations include hospitals and surgery sites equipped to perform spinal surgery.
{4}------------------------------------------------
- Indications for Use: The Kestrel™ Buttress Plate System is indicated for use to stabilize the allograft or autograft at one level (L1-S1) as an aid to spinal fusion and to provide temporary stabilization and augment development of a solid spinal fusion. It may be used alone or with other anterior, or anterolateral spinal systems made of compatible materials. This device is not intended for load bearing applications.
## Basis for Substantial Equivalence:
The KestreI™ Buttress Plate System has been subjected to risk analysis, engineering analysis and testing to recognized standards and the worst-case size has been demonstrated to be substantially equivalent to the predicate device, K092659.
The technological characteristics were found to be substantially equivalent in terms of design, sizes, materials (biocompatibility profile and processing), and mechanical strength.
- Conclusion: The conclusions drawn from the nonclinical tests demonstrate that the subject device is substantially equivalent to the leqally marketed predicate device.